The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Exciting insights into the role of ROR1 in CLL
Thomas J. Kipps, MD, PhD from the University of California, San Diego, CA discusses the role of embryonic protein ROR1 in the progression of chronic lymphocytic leukemia (CLL). Expressed on leukemic cells, ROR1 is a potential marker and target for CLL treatments. Prof. Kipps describes exciting data looking into the biology and signaling pathways of ROR1, and how targeted ROR1 therapies could be combined with other targeted therapies, such as ibrutinib and idelalisib, to provide a two-hit treatment approach. This interview was recorded the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY.
